法國BFM電視臺：法國校車事故造成兩人死亡。

China's National Medical Products Administration approved Beijing Yimiao Shenzhou Biopharmaceutical Co. Ltd.'s polatuzumab vedotin injection, marketed as Saibohua, for adults with relapsed or refractory large B‑cell lymphoma after two or more lines of systemic therapy, including diffuse large B‑cell lymphoma (not otherwise specified), grade 3b follicular lymphoma and high‑grade B‑cell lymphoma. The approval provides a new treatment option for these patient groups.

羅素2000指數下跌2.5%，勢將創下6月5日以來最大單日跌幅。